Cardiovascular Journal of Africa: Vol 27 No 4 (July/August 2016)

54 / 92

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 4, July/August 2016 256 AFRICA
zidovudine, trimethoprim-sulfamethoxazole and antimalarial
medications. The higher prevalence seen in HIV-positive patients
on HAART, compared to the HIV-positive HAART-naïve
group may have been from the use of lopinavir and zidovudine
medications.
There were some limitations of this study. First, we were
unable to carry out biochemical tests such as serum electrolytes
and lipograms in any of the subjects. Second, we were unable to
determine the actual time of HIV infection, and by extension, the
duration of HIV infection. Third, since this was an observational,
cross-sectional study, we were unable to infer causality.
Conclusion
The prevalence of ECG abnormalities was higher in the
HIV-positive patients on HAART (93%) and HIV-positive
HAART-naïve patients (73%) compared to the apparently healthy
controls. The use of ECG is helpful in cardiovascular evaluation
of this patient population, especially in resource-poor countries.
References
1. US Global Health Policy Fact Sheet 2009. The Henry J Kaiser Family
Foundation.
2. Regional Fact Sheet 2012. Sub-Saharan Africa.
3. UNAIDS 2012. Global Report: Annexes.
4. Federal Republic of Nigeria. Global AIDS Response Country Progress
Report, Nigeria, 2012.
documents/NGA_narrative_report .
5. AIDS Epidemic Update 2009. Impact of increased access to treatment
on epidemiological trends. 2009: 16–18. Available at
org/en/ knowledge Centre/ HIV Data/Methodology.
6. United Nation’s General Assembly Special Session (UNGASS) Country
Progress Report for Nigeria (Jan 2008 to Dec 2009) in March 2010,
indicator 24: 35.
country_progress_report_en.pdf.
7. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk
factors in HIV patients –Association with antiretroviral therapy. Results
from the DAD study. AIDS 2003; 17: 1179–1193.
8. Frerichs FC, Dingemans KP, Brinkman K. Cardiomyopathy with
mitochondrial damage associated with nucleoside reverse-transcriptase
inhibitors. N Engl J Med 2002; 347: 1895–1896.
9. Powderly WG. Long-term exposure to lifelong therapies. J Acquir
Immune Defic Syndr 2002; 29(Suppl 1): S28–40.
10. Bozzette SA, Ake CF, Tam HK, et al . Cardiovascular and cerebro-
vascular events in patients treated for human immunodeficiency virus
infection. N Engl J Med 2003; 348: 702–710.
11. Busari OA, Opadijo OG, Adeyemi OA. Cardiac diseases in HIV and
AIDS. Internet J Cardiol 2008. Available at jour-
nal/the_internet_journal_of_cardiology/volume_5_number_2_6/article/
cardiac_diseases_in_hiv_and_aids.html.
12. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G; Gruppo Italiano
per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators.
Cardiac involvement in the acquired immunodeficiency syndrome: a
multicenter clinical-pathological study. AIDS Res Hum Retroviruses
1998; 14: 1071–1077.
13. Sani MU, Okeahialam BN, Ukoli CO. Electrocardiographic abnormali-
ties in Nigerian AIDS patients. Cardiologie Tropicale 2004; 30: 3–6.
14. Andrew C, Birgit G, Jacqueline N, et al. Strategies for Management of
Antiretroviral Therapy (SMART) study. AIDS 2008; 22: 257–267.
15. Araoye MO. Reseach Methodology with Statistics for Health and Social
Dciences. Ilorin: Nathadex, 2003: 117–121.
16. Danbauchi SS, Sani BG, Alhassan AM, et al. Echocardiographic
features of HIV/AIDS subjects on 1–2 years of ARV drugs in Nigeria.
Available at
17. Centre for Disease Control. 1993 revised classification system for HIV
infection and expanded surveillance case definition for AIDS among
adolescents and adults. HIV/AIDS surveillance report, Atlanta 1993;
1–23.
18. Henry WL, De Maria A, Gramiak R, et al. Report of the American
Society of Echocardiography committee on nomenclature and stand-
ards in 2-D echocardiography. Circulation 1980; 62: 212–217.
19. Okoye IC. Electrocadiographic abnormalities of newly diagnosed
patients with HIV/AIDS who are not on HAARTS at UNTH, Enugu.
Part II dissertation. West Africa College of Physicians April, 2010.
20. Mouanodji M, Mbaingnro D, Brendon P. Clinical outline of AIDS
patients with cardiac manifestations in Africa. Int conf AIDS 1994; 10:
266.
21. Levy WS, Simon GL, Rios JC, Ross AM. Prevalence of cardiac abnor-
mality in HIV infection. Am J Cardiol 1989; 63: 86–89.
22. Herst JA, Shepherd FA, Liu P. Prospective assessment of cardiac func-
tion in patients with Kaposi sarcoma and AIDS. Clin Inv Med 1991;
14: 21–27.
23. Shikuma CM, Zackin R, Sattler F, et al. Changes in weight and lean
body mass during highly active antiretroviral therapy. Clin Infect Dis
2004; 39: 1223–1230.
24. Araoye MA. Basic Electrocardiography. 2nd edn. Ibadan: Spectrum
Books, 2012: 43.
25. Di Paolo FM, Schmied C, Zerguini YA. The athlete’s heart in adolescent
Africans: An electrocardiographic and echocardiographic study. J Am
Coll Cardiol 2012; 59: 1029–1036.
26. Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human
immunodeficiency virus infection. Res Virol 1993; 144: 225–231.
27. Okeahialam BN, Anjorin FL. Echocardiographic study of the heart in
AIDS. The Jos experience. Trop Card 2000; 26: 3–6.
28. Aaron LB, Malissa JW. Athlete’s heart and cardiovascular care of the
athlete, scientific and clinical update. Circulation 2011; 123: 2723–2735.
29. Trivedi SV, Bhattacharya A, Amichandwala K. Evaluation of cardiovas-
cular status in severe leptospirosis. J Assoc Physic Ind 2003; 51: 951–953.
30. Charbit B, Gayat E, Voiriot P, et al. Effects of HIV protease inhibitors
on cardiac conduction velocity in unselected HIV-infected patients. Clin
Pharmacol Therapeut 2011; 90: 442–448.
31. Araoye MA. Basic Electrocardiography. 2nd edn. Ibadan: Spectrum
Books, 2012; 102–103.
32. Barbaro G, Barbarini G, Di Lorenzo G. Early impairment of systolic
and diastolic function in asymptomatic HIV-positive patients: a multi-
center echocardiographic and echo-Doppler study. AIDS Res Hum
Retroviruses 1996; 12: 1559–1563.
33. Lipshultz SE, Easley KA, Orav EJ, et al. Left ventricular structure
and function in children infected with human immunodeficiency virus.
Circulation 1998; 97: 1246–1256.
34. Martinez-Garcia T, Sobrino JM, Pujol E, et al. Ventricular mass and
diastolic function in patients infected by the human immunodeficiency
virus. Heart 2000; 84: 620–624.
35. Samaan SA, Foster A, Raizada V, et al. Myocardial atrophy in acquired
immunodeficiency syndrome-associated wasting. Am Heart J 1995; 130:
823–827.
36. Lund KC, Wallace KB. Direct effects of nucleoside reverse transcriptase
inhibitors on rat cardiac mitochondrial bioenergetics. Mitochondrion
2004; 4: 193–202.